Skip to main content
. Author manuscript; available in PMC: 2021 Mar 16.
Published in final edited form as: Obstet Gynecol. 2018 Nov;132(5):1252–1264. doi: 10.1097/AOG.0000000000002933

Fig. 3.

Cohort 2 patient disposition. *Two women were randomized but not treated. Women may have listed more than one reason for premature discontinuation, but only the primary reasons are included. Other category is a combination of pregnancy, exclusionary medication received, and other categories. QD, daily; 0.5/0.1, 0.5 mg estradiol/0.1 mg norethindrone acetate; 1.0/0.5, 1.0 mg estradiol/0.5 mg norethindrone acetate.

Fig. 3.